SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 12, 2004
----------------
A.P. PHARMA, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 1-16109 94-2875566
- ---------------------------- ---------- -----------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
123 SAGINAW DRIVE, REDWOOD CITY, CALIFORNIA 94063
--------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code:
(650) 366-2626
--------------
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5.
On August 12, 2004, the Registrant issued a press release
announcing its preliminary clinical data results from the second
part of the Phase 2 trial using APF112 for the treatment of pain
following inguinal hernia procedures and initial Phase 1 data for
APF530 that is designed to provide relief from chemotherapy-
induced nausea and vomiting following a single subcutaneous
injection. The press release is attached hereto as Exhibit 99.1
and incorporated herein by reference.
ITEM 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press release dated August 12, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
A.P. PHARMA, INC.
Date: August 12, 2004 By: /S/ Michael O'Connell
------------------ ----------------------
Michael P. J. O'Connell,
President and Chief
Executive Officer
EXHIBIT INDEX
99.1 Press release dated August 12, 2004.
(continued from previous page)